• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Seminars in thoracic and cardiovascular surgery. Pediatric cardiac surgery annual >Ventricular Assist Devices for Neonates and Infants
【24h】

Ventricular Assist Devices for Neonates and Infants

机译：用于新生儿和婴儿的室心辅助装置

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Heart transplant waitlist survival in pediatric patients has been substantially improved since the introduction of pediatric-specific ventricular assist device. In neonates and infants, however, the waitlist mortality remains very high. The only long-term device currently approved for use in the United States is the Berlin Heart EXCOR, but this device has several important limitations because of the paracorporeal, pulsatile nature of the underlying technology. We reviewed Stanford ventricular assist experience on patients less than 1 year old since 2004. It shows overall 1-, 3-, and 5-year survival were 68%, 62%, and 49%, respectively. There are statistically significant differences in survival among cardiomyopathy group, end-stage congenital heart disease group and single ventricle group. In order to improve outcomes in this extremely high risk group, modifications were made to anticoagulation protocols, cannulation strategy in hypertrophic cardiomyopathy patients, and preferential use of continuous flow pumps in a single ventricle patients. The long-waited PumpKIN trial testing the Jarvik 2015 is about to start with the first human implant.
机译：由于引入儿科特异性室性辅助装置以来，小儿患者的心脏移植候补人员存活率显着提高。然而，在新生儿和婴儿中，等候名称死亡率仍然很高。目前批准在美国的唯一长期设备是柏林心脏求象，但该器件具有几个重要的局限性，因为底层技术的实体，脉动性质。我们审查了自2004年以来少于1岁的患者的斯坦福心室辅助经验。它显示出总体1-，3-，5年生存率分别为68％，62％和49％。心肌病变群，末期先天性心脏病组和单脑室群体存在统计学上显着差异。为了改善这种极高的风险组中的结果，对抗凝协议，肥厚性心肌病患者的插管策略进行修饰，以及在单个心室患者中优先使用连续流量泵。长等南瓜试验测试JARVIK 2015即将开始与第一个人类植入物开始。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号